



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A single-arm phase II study of consolidation Serplulimab following hypofractionated radiotherapy with concurrent chemotherapy for patients with limited stage small cell lung cancer(ASTRUM-LC01)

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-085552
Article Type:	Protocol
Date Submitted by the Author:	20-Feb-2024
Complete List of Authors:	Wu, Yuqi; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology Deng, Lei; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology Wang, Jianyang; Cancer Hospital Chinese Academy of Medical Sciences, Department of Cardiovascular Surgery Zhang, Tao; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology Cao, Jianzhong; Shanxi Hospital of Integrated Traditional Chinese and Western Medicine, Radiation therapy Zhou, Xiaohong; Jiamusi Cancer Hospital, Department of Radiation Oncology Duan, Jianchun; Cancer Hospital Chinese Academy of Medical Sciences, Department of Medical Oncology Bi, Nan; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology
Keywords:	Respiratory tract tumours < ONCOLOGY, Immunology < THORACIC MEDICINE, RADIOTHERAPY

SCHOLARONE™  
Manuscripts

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Issue date: 4 Feb, 2024

**Title**  
**A single-arm phase II study of consolidation Serplulimab following hypofractionated radiotherapy with concurrent chemotherapy for patients with limited stage small cell lung cancer(ASTRUM-LC01)**

**Yuqi Wu<sup>1†</sup>, Lei Deng<sup>1†</sup>, Jianyang Wang<sup>1</sup>, Tao Zhang<sup>1</sup>, Jianzhong Cao<sup>2</sup>, Xiaohong Zhou<sup>3</sup>, Jianchun Duan<sup>4\*</sup>, Nan Bi<sup>1\*</sup>**

<sup>1</sup>Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Postal address: No.17 Panjiayuan South Lane, Chaoyang District, Beijing , 100021, China.

<sup>2</sup>Department of Radiation Oncology, Shanxi Province Cancer Hospital/ Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Shanxi, China. Postal address: No.3, Employee New Village, Xinghualing District, Taiyuan City, Shanxi Province, 030013, China.

<sup>3</sup>Department of Radiation Oncology, Jiamusi Cancer Hospital. Postal address: No. 37 Guanghua Road, Qianjin District, Jiamusi City, Heilongjiang Province, 154007, China.

<sup>4</sup>Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Postal address: No.17 Panjiayuan South Lane, Chaoyang District, Beijing, 100021, China.

<sup>†</sup>These authors contributed equally to this work and share first authorship.

**\* Correspondence:**

Jianchun Duan; Phone: (+86) 010-87788029; Fax: (+86) 010-87788029; Email: duanjianchun79@163.com; Postal address: No.17 Panjiayuan South Lane, Chaoyang District, Beijing , 100021, China.

Nan Bi; Phone: (+86) 13520445135; Fax: (+86) 10-87787692; Email: [binan\\_email@163.com](mailto:binan_email@163.com); Postal address: No.17 Panjiayuan South Lane, Chaoyang District, Beijing , 100021, China.

**Word count:** 1844 words.

## Abstract

**Introduction** With the inspiring results of PACIFIC trial in non-small cell lung cancer (NSCLC), and CAPIAN and IMpower133 trial in extensive-stage small cell lung cancer (SCLC), immunotherapy has increasingly gained attention. Serplulimab, a PD-1 inhibitor, showed great antitumor activity in ASTRUM-005 trial and has been recommended as first-line therapy in extensive-stage SCLC. Whether serplulimab following hypofractionation radiotherapy and chemotherapy could bring better outcomes in limited-stage SCLC remains to be answered.

**Methods and analysis** We designed a prospective multicenter single-arm phase II clinical trial to evaluate both the efficacy and safety of chemoradiotherapy and consolidation by serplulimab in limited-stage SCLC. Eligible patients will receive standard chemotherapy for 4 cycles and concurrent thoracic radiotherapy with total dose being 45Gy in 3 weeks and 3Gy dose per fraction. Prophylactic cranial irradiation is recommended for response patients. Serplulimab will be delivered afterwards every 3 weeks for up to 1 year. Based on sample size estimation, 55 patients will be enrolled in total.

**Ethics and Dissemination** Ethics approval was obtained from the Independent Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (22/236-3438).

**Registration details** This study was registered in ClinicalTrials.gov (NCT05443646).

## Strengths and limitations of this study

### Strengths

1. Serplulimab have reported the longest median overall survival time in extensive-stage small-cell lung cancer (SCLC) patients. This trial aimed at assessing drug efficacy in limited stage SCLC as consolidation therapy.
2. Hypofractionated radiotherapy was applied and might have additional benefits together with immunotherapy.

### Limitations

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1. Single-arm design without a control group.
2. Limited number of enrolled patients.

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

## Introduction

Small cell lung cancer (SCLC) originates from epithelial cells with neuroendocrine differentiation. It accounts for 15%–20% of the total number of lung cancers<sup>1</sup>. SCLC is characterized by high malignancy, strong invasiveness, early metastasis, and rapid disease progression, with an extremely poor prognosis. According to the Veterans Administration Lung Study Group (VALSG) stage, SCLC can be further divided into limited stage and extensive stage. Approximately 30%-40% patients are initially diagnosed with limited-stage SCLC (LS-SCLC)(1). At present, surgery and chemotherapy with concurrent radiotherapy are standard treatment regimens for LS-SCLC. However, surgery is only applicable for a few patients with early SCLC, accounting for approximately 2%–5%. The combination of definitive thoracic radiotherapy and platinum-based chemotherapy followed by prophylactic cranial irradiation (PCI) in responsive patients has been the standard regimen in the past two decades. The median overall survival has been reported to be 25-30 months in recent years(2).

The progress of small cell lung cancer research was slow in the 20<sup>th</sup> century until the encouraging results of the Impower133 study(3) and CASPIAN study(4) shed light on the treatment of extensive-stage SCLC (ES-SCLC). Thereafter, more PD-1/PD-L1 inhibitors were proven to be effective as first-line treatment for ES-SCLC, including adebrelimab(5), pembrolizumab(6), serplulimab(7), etc. Among them, patients treated with serplulimab had the longest median overall survival time (OS) considering the absolute value (15.8 vs. 11.1 months for placebo group; hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.50–0.76; descriptive  $p < 0.001$ ). Subgroup analysis of OS by race showed similar trends to improved survival in Asians and non-Asians(7).

However, evidence of consolidation immunotherapy for LS-SCLC is limited. The STIMULI study, a phase II randomized controlled clinical study, failed to prove the superiority of consolidation immunotherapy consisting of nivolumab and ipilimumab(8). One possible reason for this may be the unexpectedly high rate of grade  $\geq 3$  adverse events (62% vs 25% in the experimental and observation arms, respectively).

A randomized, placebo-controlled phase III trial, the ADRIATIC study, investigating the efficiency of durvalumab with or without tremelimumab following concurrent chemoradiotherapy in LS-SCLC is ongoing. With the inspiring results of serplulimab in ES-SCLC, we hypothesized that serplulimab might show certain efficacy in LS-SCLC with acceptable toxicity profiles.

Moreover, the optimal radiotherapy fractionation for LS-SCLC has been under debate. The hyperfractionation regimen (45 Gy/1.5 Gy bid/3 weeks) has been the standard regimen according to the Intergroup 0096 study since 1999(9). A new phase II trial suggested that a higher dose of 60 Gy in 40 fractions may further improve survival. However, this twice-daily mode significantly increased the occurrence of grade  $\geq 3$  acute esophagitis compared with the once-daily mode (32% vs 16%,  $p < 0.001$  in the Intergroup 0096 trial). The increased load to patients, physicians, and medical equipment of twice-daily radiotherapy is significantly limited in practice, and the once-daily schedule is more widely used(10). In the CONVERT trial and RTOG 0538 trial, the 66 Gy/70 Gy once-daily arm showed similar OS and toxicity to the 45 Gy twice-daily arm(11, 12). Recently, several retrospective and prospective phase II studies showed that hypofractionated radiotherapy regimens with total doses ranging from 40 Gy to 55 Gy were similarly effective as the 45 Gy twice-daily regimen, with similar incidences of grade  $\geq 3$  acute esophagitis and pneumonia(13-16). Both conventional and hypofractionated radiotherapy are recommended by the updated version of the National Comprehensive Cancer Network (NCCN) guidelines.

Additionally, a hypofractionated radiotherapy regimen may have a better synergistic effect with immunotherapy. Preclinical studies have suggested that a higher dose could remodel the tumor microenvironment by upregulating MHC-I expression, increasing CD8+ T-cell infiltration, and upgrading the ratio of proinflammatory macrophages(17-19). However, myeloid-derived suppressor cells and regulatory T cells accumulate as well, together with induction of the DNA exonuclease Trex1, which attenuates the immunogenicity of cancer cells(20-22). Thus, hypofractionated radiation could potentially lead to a greater response to immunotherapy as a tradeoff.

Survival has reached a plateau for patients with cytotoxic chemotherapy and

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

radiotherapy. With the development of immunotherapy in recent years, it is acknowledged that the combination of radiotherapy and immunotherapy has a synergistic effect. It has been proven that radiotherapy induces immunogenic death in tumor cells, promotes the release and presentation of tumor antigens, activates cytotoxic T lymphocytes, returns tumor cells to the tumor environment, activates the immunogenicity of the whole body, reconstructs the tumor microenvironment, and exerts a remote effect. In addition, immunotherapy normalizes tumor blood vessels, relieves anoxia of the tumor microenvironment, and makes tumors more sensitive to radiation(20).

Synergy between radiotherapy and immunotherapy has been confirmed and applied in clinical practice in recent years. Previous preclinical studies suggested that a higher irradiation dose might trigger cell death more effectively, upregulate the expression of immunogenetic cell surface markers, and better induce proinflammatory responses to enhance the clearance of tumor cells(17, 23, 24). Thus, hypofractionation might be a better complement to immunotherapy.

Based on previous evidence and urgent clinical needs, we designed this investigator-initiated multicenter phase II trial, the ASTRUM-LC01 study, to investigate the clinical efficacy and safety of serplulimab consolidation therapy after concurrent hypofractionated radiotherapy with chemotherapy in limited-stage small cell lung cancer.

## Methods and analysis

### Study design

ASTRUM-LC01 will be carried out as a multicenter single-arm phase II clinical trial (ClinicalTrials.gov identifier NCT05443646). Naïve LS-SCLC patients will receive concurrent chemoradiotherapy, PCI, and subsequent serplulimab therapy. The flowchart of this study is presented in Figure 1.

### Research objectives

The primary objective of this trial was to evaluate improvements in PFS. PFS is defined as the time from the date of beginning of any antitumor therapy to the date of



any documented disease progression or death due to any cause.

The secondary objectives include evaluating overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), and safety evaluation. OS is the period between the beginning of any antitumor therapy to any documented death due to any cause. ORR is the proportion of subjects achieving complete response (CR) and partial response (PR) as assessed by RECIST 1.1. TTF means time to disease progression, death, withdrawal due to adverse events, patient refusal to continue the study, or use of a new treatment from the very first date of treatment administration.

**Participants**

Detailed inclusion and exclusion criteria are presented in Table 1. Patients with histologically or cytologically confirmed SCLC and staged at a limited stage were considered potential participants. Patients must be 18-75 years of age, with a Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1, at least one evaluable lesion according to version 1.1 of the Response Evaluation Criteria in Solid Tumors, and no serious abnormalities in hematopoietic function or cardiac, hepatic, or renal function or immunodeficiency. Patients who were suitable for surgery but refused were included. Detection of PD-L1 expression levels is highly recommended but not essential. All patients will be informed of the potential benefit and risk of this trial. Informed consent signed by every participant is requested.

**Treatments**

All eligible patients will receive four cycles of chemotherapy after screening. The regimens are etoposide 100 mg/m<sup>2</sup> intravenously on days 1-3 in combination with cisplatin 75 mg/m<sup>2</sup> intravenously on day 1 (EP) or carboplatin AUC=5 every 3 weeks (EC). The selection of the regimen depends on the decision of the investigators. In cases of intolerance to chemotherapeutic agents, dose modifications are allowed twice according to the prescribing information for cisplatin/carboplatin and etoposide.

Thoracic radiation will be initiated after no later than two cycles of chemotherapy(25). It is planned to target the primary tumor and involved mediastinal lymph node regions. For simulation, 4D-CT simulation positioning and enhanced CT positioning image scanning should be performed as much as possible. The scanning

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

slice thickness was 0.3 cm. A total of 45 Gy in 15 fractions over 3 weeks will be delivered. PCI is routinely scheduled for patients without progression after chemoradiotherapy. 25Gy in 10 fractions over 2 weeks to the brain will be prescribed. Image guided-intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) techniques are needed. Treatment plans should meet organ dose constraints, as listed in Table 2. Patients without disease progression will receive an intravenous infusion of 300 mg serplulimab every 3 weeks. Treatment with serplulimab should be continued until disease progression, intolerable toxicity, withdrawal of consent, or a maximum of 1 year.

### Assessment

Treatment response will be assessed every 4 cycles during serplulimab treatment with chest CT and brain magnetic resonance imaging (MRI) and ultrasonic examination when necessary. Contrast-enhanced CT of the neck, thorax and abdomen is preferred. Brain CT or PET is allowed if MRI is contraindicated. Each CT and MRI scan needs to be reviewed by radiologists and radiation oncologists. Subsequent assessments and follow-up will be performed every 6 weeks during the first 48 weeks of treatment and every 9 weeks after 48 weeks.

Patients will be interviewed face to face during their routine hospital visits and by telephone 1-2 weeks after delivery. Adverse events will be evaluated at each visit. Grades of side effects using CTCAE 5.0 and their relationship with immunotherapy will be assessed by the research team members. Grade 2 pneumonia and grade 3 to 4 adverse effects will be managed by drug interruption and symptomatic treatment. Of note, dose reduction of serplulimab is not permitted.

### Statistical considerations and analysis

The primary purpose of the phase II study was to evaluate the improvement in PFS for LS-SCLC patients. The study adopted the design of a superior test, and the sample size was calculated using historical data as a reference. The median PFS of LS-SCLC patients treated with standard CRT and PCI is approximately 15 months. The assumption of 80% power, a significance level of 10%, a hazard ratio of 0.65, an accrual period of 12 months, and a minimum follow-up of 27 months resulted in a

sample size of 50 individuals. Considering a maximum drop-out rate of 10%, a total of 55 patients will be recruited in ASTRUM-LC01.

All collected data will enter the computer. Measurement data will be described as the median, mean value and standard deviation. Enumeration data will be described as the number of cases and percentage. Kaplan–Meier survival analysis and Cox regression will be applied for survival analysis. The log-rank method will be used for comparison between subgroups. A value of 0.05 was set as the statistically significant standard in this trial.

**Monitoring**

The study group will review data about treatment efficacy and safety. Trial monitoring is planned every half-a-year, and the monitoring committee will modify the protocol if necessary. Trial progress will be monitored by the study group, same as safety and protocol compliance.

**Discussion**

Small cell lung cancer is a highly aggressive cancer with poor prognosis. Therefore, there is a great need to improve treatment efficacy, especially in the era of precision radiation and immunotherapy. Based on current evidence in NSCLC and extensive-stage SCLC, immunotherapy has shown high efficacy as first-line therapy or consolidation therapy in locally advanced NSCLC. Whether consolidation immunotherapy would bring added benefits to traditional concurrent chemoradiotherapy has attracted much attention worldwide. This clinical trial would help to answer this question. Improved survival with acceptable toxicity is expected and hopefully further ameliorates the treatment paradigm.

**Ethics and dissemination**

This study received ethical approval from the Independent Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (22/236-3438). This protocol has been accepted for poster presentation at the European Lung Cancer Congress (ELCC) 2024. Investigators

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

will obtain written consent from patients willing to participate in the trial.

### List of abbreviation

CI: confidence interval

CR: complete response

EC: etoposide and carboplatin

ECOG PS: Eastern Cooperative Oncology Group performance status

EP: etoposide and cisplatin

ES-SCLC: extensive-stage small cell lung cancer

HR: hazard ratio

IMRT: image guided-intensity modulated radiation therapy

LS-SCLC: limited-stage small cell lung cancer

MRI: magnetic resonance imaging

ORR: objective response rate

OS: overall survival

PCI: prophylactic cranial irradiation

PFS: Progression-free survival

PR: partial response

SCLC: Small cell lung cancer

TTF: time to treatment failure

VALSG: Veterans Administration Lung Study Group

VMAT: volumetric modulated arc therapy

### Authors' Contributions

The study was designed by YW, LD, JC and NB. YW and JC developed the statistical analysis plan. YW and LD were major contributors in writing the manuscript. LD, JW, TZ, JC and XZ perform the research and monitor progress. JC, XZ and NB modified the manuscript. All authors read and approved the final manuscript.

### Competing interests

The authors declare that they have no competing interests.

**Funding statement**

This study was supported by the Beijing Municipal Science & Technology Commission (No. Z221100007422011).

**Acknowledgments**

Serplulimab in this trial will be provided by Shanghai Henlius Biotech, Inc., for free. This had no influence on the trial design, statistical analysis, or publication.

**Reference**

1. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. *Nat Rev Dis Primers*. 2021;7(1):3.
2. Bogart JA, Waqar SN, Mix MD. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. *J Clin Oncol*. 2022;40(6):661-70.
3. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). *J Clin Oncol*. 2021;39(6):619-30.
4. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *Lancet*. 2019;394(10212):1929-39.
5. Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2022;23(6):739-47.
6. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csoszi T, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. *J Clin Oncol*. 2020;38(21):2369-79.
7. Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. *JAMA*. 2022;328(12):1223-32.
8. Peters S, Pujol JL, Dafni U, Domine M, Popat S, Reck M, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. *Ann Oncol*. 2022;33(1):67-79.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Superior (ABES).

9. Turrisi AT, 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med*. 1999;340(4):265-71.
10. Farrell MJ, Yahya JB, Degnin C, Chen Y, Holland JM, Henderson MA, et al. Radiation Dose and Fractionation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns. *Clin Lung Cancer*. 2019;20(1):13-9.
11. Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, et al. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. *J Clin Oncol*. 2023;41(13):2394-402.
12. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Oncol*. 2017;18(8):1116-25.
13. Socha J, Guzowska A, Tyc-Szczepaniak D, Szczesna A, Kepka L. Hypofractionated conformal radiotherapy in combination with chemotherapy in limited disease small cell lung cancer patients. *Pneumonol Alergol Pol*. 2014;82(2):105-15.
14. Gronberg BH, Halvorsen TO, Flotten O, Brustugun OT, Brunsvig PF, Aasebo U, et al. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. *Acta Oncol*. 2016;55(5):591-7.
15. Xia B, Hong LZ, Cai XW, Zhu ZF, Liu Q, Zhao KL, et al. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2015;91(3):517-23.
16. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, et al. Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. *Radiother Oncol*. 2012;102(2):263-7.
17. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. *J Exp Med*. 2006;203(5):1259-71.
18. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8<sup>+</sup> T cells: changing strategies for cancer treatment. *Blood*. 2009;114(3):589-95.
19. Sary V, Wolf B, Unterleuthner D, List J, Talic M, Laengle J, et al. Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer. *J Immunother Cancer*. 2020;8(2).
20. Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, et al. The Reciprocity between Radiotherapy and Cancer Immunotherapy. *Clin Cancer Res*. 2019;25(6):1709-17.
21. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour



immunogenicity. *Nat Commun.* 2017;8:15618.

22. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? *Nat Rev Clin Oncol.* 2017;14(6):365-79.

23. Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM. Building immunity to cancer with radiation therapy. *Cancer Lett.* 2015;368(2):198-208.

24. Formenti SC, Demaria S. Systemic effects of local radiotherapy. *Lancet Oncol.* 2009;10(7):718-26.

25. Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. *Ann Oncol.* 2013;24(8):2088-92.

Figure Legends & Tables

**Figure 1** Flowchart of the ASTRUM-LC01 study. SCLC: Small cell lung cancer; ECOG PS: Eastern Cooperative Oncology Group performance status; PCI: Prophylactic cranial irradiation; PFS: Progression-free survival; OS: Overall survival; ORR: Objective response rate; DCR: TTF: Time to treatment failure.

**Table 1** Inclusion criteria and exclusion criteria.

Inclusion criteria	Exclusion criteria
Age 18-75 years.	Histologically or cytologically confirmed mixed SCLC.
Histologically or cytologically confirmed SCLC.	Suitable for surgery.
Limited stage SCLC.	Patients with other active malignancies within 5 years or at the same time. Localized tumors that have been cured such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, and breast cancer in situ are acceptable.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

Score of Eastern Cooperative Oncology Group performance status (ECOG PS) being 0 or 1.	Patients with pleural, pericardial effusions, or ascites requiring clinical intervention.
Without previous anti-tumor treatment history	Uncontrolled or symptomatic hypercalcemia ( $> 1.5$ mmol/L ionized calcium or calcium $> 12$ mg/dL or corrected serum calcium $> \text{ULN}$ ).
Without serious abnormalities in hematopoietic function or cardiac, hepatic, or renal function, or immunodeficiency.	Patients with peripheral neuropathy $\geq$ grade 2 by CTCAE.
Expected survival of at least 3 months	Patients with human immunodeficiency virus (HIV), Hepatitis B or C infection.
Voluntarily participate in this clinical study and signed the informed consent form.	Patients with active pulmonary tuberculosis, previous and current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, and severe impaired pulmonary function as judged by the investigator.
	Subjects with known active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to be enrolled.

**Table 2 Organ at risk dose constrains.**

Organ at risk		
Lung	V20 $< 25\%$	mean lung dose $\leq 15$ Gy
Spinal cord PRV*	Dmax $< 42$ Gy	
Esophagus	Dmax $< 50$ Gy	mean dose $< 34$ Gy
Heart	V30 $< 50\%$	




Hippocampus	Dmax < 9 Gy	
Hippocampus PRV**	Dmax < 12 Gy	

\*5 mm expansion outside the spinal cord to form planning organ-at-risk volume (PRV)

\*\* 2 mm expansion outside hippocampus to form PRV

For peer review only

Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.



Flowchart of the ASTRUM-LC01 study.

1411x793mm (72 x 72 DPI)

# BMJ Open

## ASTRUM-LC01 Study Protocol: A Single-arm Phase II Study of Consolidation Serplulimab Following Hypofractionated Radiotherapy with Concurrent Chemotherapy for Patients with Limited Stage Small Cell Lung Cancer

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-085552.R1
Article Type:	Protocol
Date Submitted by the Author:	30-Nov-2024
Complete List of Authors:	Wu, Yuqi; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology Deng, Lei; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology Wang, Jianyang; Cancer Hospital Chinese Academy of Medical Sciences, Department of Cardiovascular Surgery Zhang, Tao; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology Cao, Jianzhong; Shanxi Hospital of Integrated Traditional Chinese and Western Medicine, Radiation therapy Zhou, Xiaohong; Jiamusi Medical College, Department of Radiation Oncology Duan, Jianchun; Cancer Hospital Chinese Academy of Medical Sciences, Department of Medical Oncology Bi, Nan; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Oncology, Immunology (including allergy)
Keywords:	Respiratory tract tumours < ONCOLOGY, Immunology < THORACIC MEDICINE, RADIOTHERAPY

SCHOLARONE™  
Manuscripts

**Strengths and limitations of this study**

Strengths: This study applies the first PD-1 monoclonal antibody which is effective in extensive-stage SCLC, serplulimab, to the consolidation therapy of limited-stage SCLC following hypofractionated radiotherapy and concurrent chemotherapy.

Limitations: The single-arm design and reliance on historical controls may limit the generalizability of the trial's findings.

**Title**

**ASTRUM-LC01 Study Protocol: A Single-arm Phase II Study of Consolidation Serplulimab Following Hypofractionated Radiotherapy with Concurrent Chemotherapy for Patients with Limited Stage Small Cell Lung Cancer**

**Yuqi Wu<sup>1†</sup>, Lei Deng<sup>1†</sup>, Jianyang Wang<sup>1</sup>, Tao Zhang<sup>1</sup>, Jianzhong Cao<sup>2</sup>, Xiaohong Zhou<sup>3</sup>, Jianchun Duan<sup>4\*</sup>, Nan Bi<sup>1\*</sup>**

<sup>†</sup>These authors contributed equally to this work and share first authorship.

**\* Correspondence:**

Jianchun Duan; Phone: (+86) 010-87788029; Fax: (+86) 010-87788029; Email: [duanjianchun79@163.com](mailto:duanjianchun79@163.com); Postal address: No.17 Panjiayuan South Lane, Chaoyang District, Beijing , 100021, China.

Nan Bi; Phone: (+86) 13520445135; Fax: (+86) 10-87787692; Email: [binan\\_email@163.com](mailto:binan_email@163.com); Postal address: No.17 Panjiayuan South Lane, Chaoyang District, Beijing , 100021, China.

**Word count:** 2246 words.

## Introduction

Small cell lung cancer (SCLC) originates from epithelial cells with neuroendocrine differentiation. It accounts for 15%–20% of the total number of lung cancers[1]. SCLC is characterized by high malignancy, strong invasiveness, early metastasis, and rapid disease progression, with an extremely poor prognosis. According to the Veterans Administration Lung Study Group (VALSG) stage, SCLC can be further divided into limited stage and extensive stage. Approximately 30%-40% patients are initially diagnosed with limited-stage SCLC (LS-SCLC)[1]. At present, surgery and chemotherapy with concurrent radiotherapy are standard treatment regimens for LS-SCLC. However, surgery is only applicable for a few patients with early SCLC, accounting for approximately 2%–5%. The combination of definitive thoracic radiotherapy and platinum-based chemotherapy followed by prophylactic cranial irradiation (PCI) in responsive patients has been the standard regimen in the past two decades. The median overall survival has been reported to be 25-30 months in recent years[2].

The progress of small cell lung cancer research was slow in the 20<sup>th</sup> century until the encouraging results of the Impower133 study[3] and CASPIAN study[4] shed light on the treatment of extensive-stage SCLC (ES-SCLC). Thereafter, more PD-1/PD-L1 inhibitors were proven to be effective as first-line treatment for ES-SCLC[5-7]. Among them, patients treated with serplulimab, the first PD-1 inhibitor showed efficacy as first-line systematic treatment according to the ASTRUM-005 trial, had the longest median overall survival time (OS) considering the absolute value (15.8 vs. 11.1 months for placebo group; hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.50–0.76; descriptive  $p < 0.001$ ). Subgroup analysis of OS by race showed similar trends to improved survival in Asians and non-Asians[7].

However, evidence of consolidation immunotherapy for LS-SCLC is limited. The STIMULI study, a phase II randomized controlled clinical study, failed to prove the superiority of consolidation immunotherapy consisting of nivolumab and ipilimumab[8]. One possible reason for this may be the unexpectedly high rate of grade

1  
2  
3  
4  $\geq 3$  adverse events (62% vs 25% in the experimental and observation arms, respectively).  
5  
6 A randomized, placebo-controlled phase III trial, the ADRIATIC study, which  
7 investigating the efficiency of durvalumab following concurrent chemoradiotherapy in  
8 LS-SCLC, was ongoing when we designed this trial[9]. It has recently represented a  
9 significant advancement in both median PFS (16.6 months vs. 9.2 months,  $p=0.02$ ) and  
10 OS (55.9 months vs. 33.4 months,  $p=0.01$ )[10]. These results suggested the importance  
11 of correct combination of immunotherapy and traditional chemoradiotherapy. With the  
12 inspiring results of serplulimab in ES-SCLC, we hypothesized that serplulimab might  
13 show promising efficacy in LS-SCLC with acceptable toxicity profiles.  
14  
15

16  
17 Moreover, the optimal radiotherapy fractionation for LS-SCLC has been under  
18 debate. The hyperfractionation regimen (45 Gy/1.5 Gy bid/3 weeks) has been the  
19 standard regimen according to the Intergroup 0096 study since 1999[11]. A new phase  
20 II trial suggested that a higher dose of 60 Gy in 40 fractions may further improve  
21 survival. However, this twice-daily mode significantly increased the occurrence of  
22 grade  $\geq 3$  acute esophagitis compared with the once-daily mode (32% vs 16%,  $p < 0.001$   
23 in the Intergroup 0096 trial). The increased load to patients, physicians, and medical  
24 equipment of twice-daily radiotherapy is significantly limited in practice, and the once-  
25 daily schedule is more widely used[12]. In the CONVERT trial and RTOG 0538 trial,  
26 the 66 Gy/70 Gy once-daily arm showed similar OS and toxicity to the 45 Gy twice-  
27 daily arm[13,14]. Recently, several retrospective and prospective phase II studies  
28 showed that hypofractionated radiotherapy regimens with total doses ranging from 40  
29 Gy to 55 Gy were similarly effective as the 45 Gy twice-daily regimen, with similar  
30 incidences of grade  $\geq 3$  acute esophagitis and pneumonia[15-18]. Both conventional  
31 and hypofractionated radiotherapy are recommended by the updated version of the  
32 National Comprehensive Cancer Network (NCCN) guidelines.  
33  
34

35  
36 Additionally, a hypofractionated radiotherapy regimen may have a better  
37 synergistic effect with immunotherapy. Preclinical studies have suggested that a higher  
38 dose could remodel the tumor microenvironment by upregulating MHC-I expression,  
39 increasing CD8+ T-cell infiltration, and upgrading the ratio of proinflammatory  
40 macrophages[19-21]. However, myeloid-derived suppressor cells and regulatory T  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

cells accumulate as well, together with induction of the DNA exonuclease Trex1, which attenuates the immunogenicity of cancer cells[22-24]. Thus, hypofractionated radiation could potentially lead to a greater response to immunotherapy as a tradeoff.

Survival has reached a plateau for patients with cytotoxic chemotherapy and radiotherapy. With the development of immunotherapy in recent years, it is acknowledged that the combination of radiotherapy and immunotherapy has a synergistic effect. It has been proven that radiotherapy induces immunogenic death in tumor cells, promotes the release and presentation of tumor antigens, activates cytotoxic T lymphocytes, returns tumor cells to the tumor environment, activates the immunogenicity of the whole body, reconstructs the tumor microenvironment, and exerts a remote effect. In addition, immunotherapy normalizes tumor blood vessels, relieves anoxia of the tumor microenvironment, and makes tumors more sensitive to radiation[22].

Synergy between radiotherapy and immunotherapy has been confirmed and applied in clinical practice in recent years. Previous preclinical studies suggested that a higher irradiation dose might trigger cell death more effectively, upregulate the expression of immunogenetic cell surface markers, and better induce proinflammatory responses to enhance the clearance of tumor cells[19,25,26]. Thus, hypofractionation might be a better complement to immunotherapy.

Based on previous evidence and urgent clinical needs, we designed this investigator-initiated multicenter phase II trial, the ASTRUM-LC01 study, to investigate the clinical efficacy and safety of serplulimab consolidation therapy after concurrent hypofractionated radiotherapy with chemotherapy in limited-stage small cell lung cancer.

## Methods and analysis

### Study design

ASTRUM-LC01 will be carried out as a multicenter single-arm phase II clinical trial (ClinicalTrials.gov identifier NCT05443646). Naïve LS-SCLC patients will receive concurrent chemoradiotherapy, PCI, and subsequent serplulimab therapy. The

flowchart of this study is presented in Figure 1.

**Research objectives**

The primary objective of this trial was to evaluate improvements in PFS. PFS is defined as the time from the date of beginning of any antitumor therapy to the date of any documented disease progression or death due to any cause.

The secondary objectives include evaluating overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), and safety evaluation. OS is the period between the beginning of any antitumor therapy to any documented death due to any cause. ORR is the proportion of subjects achieving complete response (CR) and partial response (PR) as assessed by RECIST 1.1. TTF means time to disease progression, death, withdrawal due to adverse events, patient refusal to continue the study, or use of a new treatment from the very first date of treatment administration.

**Participants**

Detailed inclusion and exclusion criteria are presented in Table 1. Patients with histologically or cytologically confirmed SCLC and staged at a limited stage were considered potential participants. Patients must be aged 18-75 years, with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1, at least one evaluable lesion according to version 1.1 of the Response Evaluation Criteria in Solid Tumors, and no serious abnormalities in hematopoietic function or cardiac, hepatic, or renal function or immunodeficiency. Patients who were suitable for surgery but refused were included. Detection of PD-L1 expression levels is highly recommended but not essential. All patients will be informed of the potential benefit and risk of this trial. Informed consent signed by every participant is requested.

**Treatments**

All eligible patients will receive four cycles of chemotherapy after screening. The regimens are etoposide 100 mg/m<sup>2</sup> intravenously on days 1-3 in combination with cisplatin 75 mg/m<sup>2</sup> intravenously on day 1 (EP) or carboplatin AUC=5 every 3 weeks (EC). The selection of the regimen depends on the decision of the investigators. In cases of intolerance to chemotherapeutic agents, dose modifications are allowed twice according to the prescribing information for cisplatin/carboplatin and etoposide.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).



Thoracic radiation will be initiated no later than two cycles after chemotherapy[27]. It is planned to target the primary tumor and involved mediastinal lymph node regions. For simulation, 4D-CT simulation positioning and enhanced CT positioning image scanning should be performed as much as possible. The scanning slice thickness was 0.3 cm. A total of 45 Gy in 15 fractions over 3 weeks will be delivered. PCI is routinely scheduled for patients without progression after chemoradiotherapy. 25Gy in 10 fractions over 2 weeks to the brain will be prescribed. Image guided-intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) techniques are needed. Treatment plans should meet organ dose constraints, as listed in Table 2. Patients without disease progression will receive an intravenous infusion of 300 mg serplulimab every 3 weeks. Treatment with serplulimab should be continued until disease progression, intolerable toxicity, withdrawal of consent, or a maximum of 1 year.

### Assessment

Treatment response will be assessed every 4 cycles during serplulimab treatment with chest CT and brain magnetic resonance imaging (MRI) and ultrasonic examination when necessary. Contrast-enhanced CT of the neck, thorax and abdomen is preferred. Brain CT or PET is allowed if MRI is contraindicated. Each CT and MRI scan needs to be reviewed by radiologists and radiation oncologists. Subsequent assessments and follow-up will be performed every 6 weeks during the first 48 weeks of treatment and every 9 weeks after 48 weeks.

Patients will be interviewed face to face during their routine hospital visits and by telephone 1-2 weeks after delivery. Adverse events will be evaluated at each visit. Grades of side effects using CTCAE 5.0 and their relationship with immunotherapy will be assessed by the research team members. Grade 2 pneumonia and grade 3 to 4 adverse effects will be managed by drug interruption and symptomatic treatment. Of note, dose reduction of serplulimab is not permitted.

### Statistical considerations and analysis

The primary purpose of the phase II study was to evaluate the improvement in PFS for LS-SCLC patients. The study adopted the design of a superior test, and the

sample size was calculated using historical data as a reference. The median PFS of LS-SCLC patients treated with standard CRT and PCI is approximately 15 months. The assumption of 80% power, a significance level of 10%, a hazard ratio of 0.65, an accrual period of 12 months, and a minimum follow-up of 27 months resulted in a sample size of 50 individuals. Considering a maximum drop-out rate of 10%, a total of 55 patients will be recruited in ASTRUM-LC01. The sample size calculation was performed using the Power Analysis and Sample Size (PASS) software, version 15.

All collected data will enter the computer. Measurement data will be described as the median, mean value and standard deviation. Enumeration data will be described as the number of cases and percentage. Kaplan–Meier survival analysis and Cox regression will be applied for survival analysis. The log-rank method will be used for comparison between subgroups. A value of 0.05 was set as the statistically significant standard in this trial.

**Monitoring**

The study group will review data about treatment efficacy and safety. Trial monitoring is planned every half-a-year, and the monitoring committee will modify the protocol if necessary. Trial progress will be monitored by the study group, same as safety and protocol compliance.

**Patient and Public Involvement**

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research

**Discussion**

Small cell lung cancer is a highly aggressive cancer with poor prognosis. Therefore, there is a great need to improve treatment efficacy, especially in the era of precision radiation and immunotherapy. Based on current evidence, immunotherapy has shown high efficacy as consolidation therapy in locally advanced NSCLC. The landscape of ES-SCLC treatment has also been significantly impacted by the increasing evidences of combining immunotherapy and chemotherapy in first line. Whether consolidation

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

immunotherapy would bring added benefits to traditional concurrent chemoradiotherapy in LS-SCLC has attracted much attention worldwide. This clinical trial was therefore designed to answer this question.

Serplulimab, a novel humanized monoclonal anti-PD-1 antibody, has emerged as a promising agent in this context. The ASTRUM-005 study demonstrated that serplulimab was the first PD-1 antibody to show positive results in the first-line treatment of ES-SCLC with advanced survival data, marking a milestone in the immunotherapy exploration process and the history of SCLC treatment[7]. Meanwhile,  $\geq$ grade 3 adverse effect of serplulimab was similar to other drugs. Hence, we expect improved survival with acceptable toxicity in this trial, with great confidence.

The optimal duration of consolidation remains controversial. At the initiation of this trial in 2022, the only trial with results published, STIMULI trial, adopted a similar design as the classic PACIFIC trial[8]. Its failure was considered to be mainly due to treatment toxicity. The GEMSTONE-301 study and the recently published ADRIATIC study have opted for a longer duration of 2 years, and both significantly prolonged survival versus placebo[9,28]. But the 2-year consolidation therapy in GEMSTONE-301 trial did not demonstrate survival benefits beyond the PACIFIC pattern. Taking both the potential benefits of extended therapy and the costs into consideration, our study set the duration of serplulimab consolidation therapy to 1 year. But whether extended exposure to immunotherapy consolidation could potentially enhance its therapeutic effects will need further investigation.

Different from conventional or hyperfractionated RT in ADRIATIC trial, hypofractionated thoracic radiation was scheduled during CRT in our study. This cost-effective regimen is permitted and recommended by NCCN guideline. Synergistic effect of RT and immunotherapy might be dose-dependent as mentioned before. Further research is necessary to define the precise parameters for combining RT with immunotherapy to achieve the best clinical outcomes.

There are some limitations of this trial. The single-arm design with small sample size may limit the generalizability of the findings. Also, since only Chinese patients

will be enrolled, the applicability of the results to other regions with different healthcare systems and patient populations.

In summary, this trial design comprehensively optimized treatment paradigm with the expectation of further improving the prognosis of LS-SCLC patients.

**Ethics and dissemination**

This study received ethical approval from the Independent Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (22/236-3438). This protocol has been accepted for poster presentation at the European Lung Cancer Congress (ELCC) 2024. Investigators will obtain written consent from patients willing to participate in the trial.

**List of abbreviation**

- CI: confidence interval
- CR: complete response
- EC: etoposide and carboplatin
- ECOG PS: Eastern Cooperative Oncology Group performance status
- EP: etoposide and cisplatin
- ES-SCLC: extensive-stage small cell lung cancer
- HR: hazard ratio
- IMRT: image guided-intensity modulated radiation therapy
- LS-SCLC: limited-stage small cell lung cancer
- MRI: magnetic resonance imaging
- ORR: objective response rate
- OS: overall survival
- PCI: prophylactic cranial irradiation
- PFS: Progression-free survival
- PR: partial response
- SCLC: Small cell lung cancer

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

TTF: time to treatment failure

VALSG: Veterans Administration Lung Study Group

VMAT: volumetric modulated arc therapy

### Authors' Contributions

The study was designed by YW, LD, JC and NB. YW and JC developed the statistical analysis plan. YW and LD were major contributors in writing the manuscript. LD, JW, TZ, JC and XZ perform the research and monitor progress. JC, XZ and NB modified the manuscript. All authors read and approved the final manuscript. NB acted as guarantor.

### Competing interests

The authors declare that they have no competing interests.

### Funding statement

This study was supported by the Beijing Municipal Science & Technology Commission (No. Z221100007422011).

### Acknowledgments

Serplulimab in this trial will be provided by Shanghai Henlius Biotech, Inc., for free. This had no influence on the trial design, statistical analysis, or publication.

### Reference

1. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primer. 2021 Jan 14;7(1):3.
2. Bogart JA, Waqar SN, Mix MD. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol. 2022 Feb 20;40(6):661–70.
3. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol Off J Am Soc Clin Oncol. 2021 Feb 20;39(6):619–30.

4. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *The Lancet*. 2019 Nov;394(10212):1929–39.

5. Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2022 Jun;23(6):739–47.

6. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csősz T, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. *J Clin Oncol*. 2020 Jul 20;38(21):2369–79.

7. Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. *JAMA*. 2022 Sep 27;328(12):1223–32.

8. Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. *Ann Oncol Off J Eur Soc Med Oncol*. 2022 Jan;33(1):67–79.

9. Senan S, Okamoto I, Lee G won, Chen Y, Niho S, Mak G, et al. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. *Clin Lung Cancer*. 2020 Mar;21(2):e84–8.

10. Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2024 Oct 10;391(14):1313–27.

11. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med*. 1999 Jan 28;340(4):265–71.

12. Farrell MJ, Yahya JB, Degnin C, Chen Y, Holland JM, Henderson MA, et al. Radiation Dose and Fractionation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns. *Clin Lung Cancer*. 2019 Jan;20(1):13–9.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).



13. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Oncol*. 2017 Aug;18(8):1116–25.
14. Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, et al. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. *J Clin Oncol*. 2023 Jan 9;JCO.22.01359.
15. Socha J, Guzowska A, Tyc-Szczepaniak D, Szczesna A, Kępa L. Hypofractionated conformal radiotherapy in combination with chemotherapy in limited disease small cell lung cancer patients. *Pneumonol Alergol Pol*. 2014;82(2):105–15.
16. Gronberg BH, Halvorsen TO, Flotten O, Brustugun OT, Brunsvig PF, Aasebo U, et al. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. *Acta Oncol*. 2016 May;55(5):591–7.
17. Xia B, Hong LZ, Cai XW, Zhu ZF, Liu Q, Zhao KL, et al. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2015 Mar 1;91(3):517–23.
18. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, et al. Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 2012 Feb;102(2):263–7.
19. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. *J Exp Med*. 2006 May 15;203(5):1259–71.
20. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8<sup>+</sup> T cells: changing strategies for cancer treatment. *Blood*. 2009 Jul 16;114(3):589–95.
21. Stry V, Wolf B, Unterleuthner D, List J, Talic M, Laengle J, et al. Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer. *J Immunother Cancer*. 2020 Aug;8(2):e000667.
22. Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, et al. The Reciprocity between Radiotherapy and Cancer Immunotherapy. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2019 Mar 15;25(6):1709–17.

23. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. *Nat Commun.* 2017 Jun 9;8:15618.

24. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? *Nat Rev Clin Oncol.* 2017 Jun;14(6):365–79.

25. Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM. Building immunity to cancer with radiation therapy. *Cancer Lett.* 2015 Nov 28;368(2):198–208.

26. Formenti SC, Demaria S. Systemic effects of local radiotherapy. *Lancet Oncol.* 2009 Jul;10(7):718–26.

27. Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. *Ann Oncol Off J Eur Soc Med Oncol.* 2013 Aug;24(8):2088–92.

28. Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol.* 2022 Feb;23(2):209–19.

**Figure Legends & Tables**

**Figure 1** Flowchart of the ASTRUM-LC01 study. SCLC: Small cell lung cancer; ECOG PS: Eastern Cooperative Oncology Group performance status; PCI: Prophylactic cranial irradiation; PFS: Progression-free survival; OS: Overall survival; ORR: Objective response rate; DCR: TTF: Time to treatment failure.

**Table 1 Inclusion criteria and exclusion criteria.**

Inclusion criteria	Exclusion criteria
--------------------	--------------------

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).



Aged 18-75 years.	Histologically or cytologically confirmed mixed SCLC.
Histologically or cytologically confirmed SCLC.	Suitable for surgery.
Limited stage SCLC.	Patients with other active malignancies within 5 years or at the same time. Localized tumors that have been cured such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, and breast cancer in situ are acceptable.
Score of Eastern Cooperative Oncology Group performance status (ECOG PS) being 0 or 1.	Patients with pleural, pericardial effusions, or ascites requiring clinical intervention.
Without previous anti-tumor treatment history	Uncontrolled or symptomatic hypercalcemia ( $> 1.5$ mmol/L ionized calcium or calcium $> 12$ mg/dL or corrected serum calcium $> \text{ULN}$ ).
Without serious abnormalities in hematopoietic function or cardiac, hepatic, or renal function, or immunodeficiency.	Patients with peripheral neuropathy $\geq$ grade 2 by CTCAE.
Expected survival of at least 3 months	Patients with human immunodeficiency virus (HIV), Hepatitis B or C infection.
Voluntarily participate in this clinical study and signed the informed consent form.	Patients with active pulmonary tuberculosis, previous and current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, and severe impaired pulmonary function as judged by the investigator.


	Subjects with known active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to be enrolled.
--	---

**Table 2 Organ at risk dose constrains.**

Organ at risk		
Lung	V20 < 25%	mean lung dose ≤ 15 Gy
Spinal cord PRV*	Dmax< 42Gy	
Esophagus	Dmax< 50 Gy	mean dose < 34 Gy
Heart	V30 < 50%	
Hippocampus	Dmax < 9 Gy	
Hippocampus PRV**	Dmax < 12 Gy	

\*5 mm expansion outside the spinal cord to form planning organ-at-risk volume (PRV)

\*\* 2 mm expansion outside hippocampus to form PRV



Flowchart of the ASTRUM-LC01 study.

253x142mm (300 x 300 DPI)

# BMJ Open

## ASTRUM-LC01 Study Protocol: A Single-arm Phase II Study of Consolidation Serplulimab Following Hypofractionated Radiotherapy with Concurrent Chemotherapy for Patients with Limited Stage Small Cell Lung Cancer

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-085552.R2
Article Type:	Protocol
Date Submitted by the Author:	27-Apr-2025
Complete List of Authors:	Wu, Yuqi; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology Deng, Lei; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology Wang, Jianyang; Cancer Hospital Chinese Academy of Medical Sciences, Department of Cardiovascular Surgery Zhang, Tao; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology Cao, Jianzhong; Shanxi Hospital of Integrated Traditional Chinese and Western Medicine, Radiation therapy Zhou, Xiaohong; Jiamusi Medical College, Department of Radiation Oncology Duan, Jianchun; Cancer Hospital Chinese Academy of Medical Sciences, Department of Medical Oncology Bi, Nan; Cancer Hospital Chinese Academy of Medical Sciences, Department of Radiation Oncology
<b>Primary Subject Heading</b>:	Oncology
Secondary Subject Heading:	Oncology, Immunology (including allergy)
Keywords:	Respiratory tract tumours < ONCOLOGY, Immunology < THORACIC MEDICINE, RADIOTHERAPY

SCHOLARONE™  
Manuscripts

**Title**

**ASTRUM-LC01 Study Protocol: A Single-arm Phase II Study of Consolidation Serplulimab Following Hypofractionated Radiotherapy with Concurrent Chemotherapy for Patients with Limited Stage Small Cell Lung Cancer**

**Yuqi Wu<sup>1†</sup>, Lei Deng<sup>1†</sup>, Jianyang Wang<sup>1</sup>, Tao Zhang<sup>1</sup>, Jianzhong Cao<sup>2</sup>, Xiaohong Zhou<sup>3</sup>, Jianchun Duan<sup>4\*</sup>, Nan Bi<sup>1\*</sup>**

<sup>†</sup>These authors contributed equally to this work and share first authorship.

**\* Correspondence:**

Jianchun Duan; Phone: (+86) 010-87788029; Fax: (+86) 010-87788029; Email: duanjianchun79@163.com; Postal address: No.17 Panjiayuan South Lane, Chaoyang District, Beijing , 100021, China.

Nan Bi; Phone: (+86) 13520445135; Fax: (+86) 10-87787692; Email: [binan\\_email@163.com](mailto:binan_email@163.com); Postal address: No.17 Panjiayuan South Lane, Chaoyang District, Beijing , 100021, China.

**Abstract**

**Introduction** With the inspiring results of PACIFIC trial in non-small cell lung cancer (NSCLC), and CAPIAN and IMpower133 trial in extensive-stage small cell lung cancer (SCLC), immunotherapy has increasingly gained attention. Serplulimab, a PD-1 inhibitor, showed great antitumor activity in ASTRUM-005 trial and has been recommended as first-line therapy in extensive-stage SCLC. Whether serplulimab following hypofractionation radiotherapy and chemotherapy could bring better outcomes in limited-stage SCLC remains to be answered.

**Methods and analysis** We designed a prospective multicenter single-arm phase II clinical trial to evaluate both the efficacy and safety of chemoradiotherapy and consolidation by serplulimab in limited-stage SCLC. Eligible patients will receive standard chemotherapy for 4 cycles and concurrent thoracic radiotherapy with total dose being 45Gy in 3 weeks and 3Gy dose per fraction. Prophylactic cranial irradiation is recommended for response patients. Serplulimab will be delivered

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

afterwards every 3 weeks for up to 1 year. Based on sample size estimation, 55 patients will be enrolled in total.

**Ethics and Dissemination** Ethics approval was obtained from the Independent Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (22/236-3438).

**Registration details** This study was registered in ClinicalTrials.gov (NCT05443646).

### Strengths and limitations of this study

1. This trial will be the first prospective study to assess hypofractionated radiotherapy combined with concurrent chemotherapy, followed by consolidation PD-1 inhibitor in limited-stage small-cell lung cancer.
2. This multicenter single-arm prospective study provides a defined treatment protocol and is helpful to obtain informed consent from participants, which is particularly important for promoting clinical research in China.
3. The efficacy evaluation will be completed separately by a blinded independent imaging center and the investigators.
4. The limited sample size may restrict the ability to detect rare adverse events.

**Word count:** 2246 words.

Introduction

Small cell lung cancer (SCLC) originates from epithelial cells with neuroendocrine differentiation. It accounts for 15%–20% of the total number of lung cancers[1]. SCLC is characterized by high malignancy, strong invasiveness, early metastasis, and rapid disease progression, with an extremely poor prognosis. According to the Veterans Administration Lung Study Group (VALSG) stage, SCLC can be further divided into limited stage and extensive stage. Approximately 30%-40% patients are initially diagnosed with limited-stage SCLC (LS-SCLC)[1]. At present, surgery and chemotherapy with concurrent radiotherapy are standard treatment regimens for LS-SCLC. However, surgery is only applicable for a few patients with early SCLC, accounting for approximately 2%–5%. The combination of definitive thoracic radiotherapy and platinum-based chemotherapy followed by prophylactic cranial irradiation (PCI) in responsive patients has been the standard regimen in the past two decades. The median overall survival has been reported to be 25-30 months in recent years[2].

The progress of small cell lung cancer research was slow in the 20<sup>th</sup> century until the encouraging results of the Impower133 study[3] and CASPIAN study[4] shed light on the treatment of extensive-stage SCLC (ES-SCLC). Thereafter, more PD-1/PD-L1 inhibitors were proven to be effective as first-line treatment for ES-SCLC[5-7]. Among them, patients treated with serplulimab, the first PD-1 inhibitor showed efficacy as first-line systematic treatment according to the ASTRUM-005 trial, had the longest median overall survival time (OS) considering the absolute value (15.8 vs. 11.1 months for placebo group; hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.50–0.76; descriptive p<0.001). Subgroup analysis of OS by race showed similar trends to improved survival in Asians and non-Asians[7].

However, evidence of consolidation immunotherapy for LS-SCLC is limited. The STIMULI study, a phase II randomized controlled clinical study, failed to prove the superiority of consolidation immunotherapy consisting of nivolumab and ipilimumab[8]. One possible reason for this may be the unexpectedly high rate of grade

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

1  
2  
3  
4  $\geq 3$  adverse events (62% vs 25% in the experimental and observation arms, respectively).  
5  
6 A randomized, placebo-controlled phase III trial, the ADRIATIC study, which  
7  
8 investigating the efficiency of durvalumab following concurrent chemoradiotherapy in  
9  
10 LS-SCLC, was ongoing when we designed this trial[9]. It has recently represented a  
11  
12 significant advancement in both median PFS (16.6 months vs. 9.2 months,  $p=0.02$ ) and  
13  
14 OS (55.9 months vs. 33.4 months,  $p=0.01$ )[10]. These results suggested the importance  
15  
16 of correct combination of immunotherapy and traditional chemoradiotherapy. With the  
17  
18 inspiring results of serplulimab in ES-SCLC, we hypothesized that serplulimab might  
19  
20 show promising efficacy in LS-SCLC with acceptable toxicity profiles.

21  
22 Moreover, the optimal radiotherapy fractionation for LS-SCLC has been under  
23  
24 debate. The hyperfractionation regimen (45 Gy/1.5 Gy bid/3 weeks) has been the  
25  
26 standard regimen according to the Intergroup 0096 study since 1999[11]. A new phase  
27  
28 II trial suggested that a higher dose of 60 Gy in 40 fractions may further improve  
29  
30 survival. However, this twice-daily mode significantly increased the occurrence of  
31  
32 grade  $\geq 3$  acute esophagitis compared with the once-daily mode (32% vs 16%,  $p < 0.001$   
33  
34 in the Intergroup 0096 trial). The increased load to patients, physicians, and medical  
35  
36 equipment of twice-daily radiotherapy is significantly limited in practice, and the once-  
37  
38 daily schedule is more widely used[12]. In the CONVERT trial and RTOG 0538 trial,  
39  
40 the 66 Gy/70 Gy once-daily arm showed similar OS and toxicity to the 45 Gy twice-  
41  
42 daily arm[13,14]. Recently, several retrospective and prospective phase II studies  
43  
44 showed that hypofractionated radiotherapy regimens with total doses ranging from 40  
45  
46 Gy to 55 Gy were similarly effective as the 45 Gy twice-daily regimen, with similar  
47  
48 incidences of grade  $\geq 3$  acute esophagitis and pneumonia[15-18]. Both conventional  
49  
50 and hypofractionated radiotherapy are recommended by the updated version of the  
51  
52 National Comprehensive Cancer Network (NCCN) guidelines.

53  
54 Additionally, a hypofractionated radiotherapy regimen may have a better  
55  
56 synergistic effect with immunotherapy. Preclinical studies have suggested that a higher  
57  
58 dose could remodel the tumor microenvironment by upregulating MHC-I expression,  
59  
60 increasing CD8<sup>+</sup> T-cell infiltration, and upgrading the ratio of proinflammatory  
macrophages[19-21]. However, myeloid-derived suppressor cells and regulatory T



cells accumulate as well, together with induction of the DNA exonuclease Trex1, which attenuates the immunogenicity of cancer cells[22-24]. Thus, hypofractionated radiation could potentially lead to a greater response to immunotherapy as a tradeoff.

Survival has reached a plateau for patients with cytotoxic chemotherapy and radiotherapy. With the development of immunotherapy in recent years, it is acknowledged that the combination of radiotherapy and immunotherapy has a synergistic effect. It has been proven that radiotherapy induces immunogenic death in tumor cells, promotes the release and presentation of tumor antigens, activates cytotoxic T lymphocytes, returns tumor cells to the tumor environment, activates the immunogenicity of the whole body, reconstructs the tumor microenvironment, and exerts a remote effect. In addition, immunotherapy normalizes tumor blood vessels, relieves anoxia of the tumor microenvironment, and makes tumors more sensitive to radiation[22].

Synergy between radiotherapy and immunotherapy has been confirmed and applied in clinical practice in recent years. Previous preclinical studies suggested that a higher irradiation dose might trigger cell death more effectively, upregulate the expression of immunogenetic cell surface markers, and better induce proinflammatory responses to enhance the clearance of tumor cells[19,25,26]. Thus, hypofractionation might be a better complement to immunotherapy.

Based on previous evidence and urgent clinical needs, we designed this investigator-initiated multicenter phase II trial, the ASTRUM-LC01 study, to investigate the clinical efficacy and safety of serplulimab consolidation therapy after concurrent hypofractionated radiotherapy with chemotherapy in limited-stage small cell lung cancer.

**Methods and analysis**

**Study design**

ASTRUM-LC01 will be carried out as a multicenter single-arm phase II clinical trial (ClinicalTrials.gov identifier NCT05443646). Naïve LS-SCLC patients will receive concurrent chemoradiotherapy, PCI, and subsequent serplulimab therapy. The

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

flowchart of this study is presented in Figure 1.

### Research objectives

The primary objective of this trial was to evaluate improvements in PFS. PFS is defined as the time from the date of beginning of any antitumor therapy to the date of any documented disease progression or death due to any cause.

The secondary objectives include evaluating overall survival (OS), objective response rate (ORR), time to treatment failure (TTF), and safety evaluation. OS is the period between the beginning of any antitumor therapy to any documented death due to any cause. ORR is the proportion of subjects achieving complete response (CR) and partial response (PR) as assessed by RECIST 1.1. TTF means time to disease progression, death, withdrawal due to adverse events, patient refusal to continue the study, or use of a new treatment from the very first date of treatment administration.

### Participants

Detailed inclusion and exclusion criteria are presented in Table 1. Patients with histologically or cytologically confirmed SCLC and staged at a limited stage were considered potential participants. Patients must be aged 18-75 years, with an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 or 1, at least one evaluable lesion according to version 1.1 of the Response Evaluation Criteria in Solid Tumors, and no serious abnormalities in hematopoietic function or cardiac, hepatic, or renal function or immunodeficiency. Patients who were suitable for surgery but refused were included. Detection of PD-L1 expression levels is highly recommended but not essential. All patients will be informed of the potential benefit and risk of this trial. Informed consent signed by every participant is requested.

### Treatments

All eligible patients will receive four cycles of chemotherapy after screening. The regimens are etoposide 100 mg/m<sup>2</sup> intravenously on days 1-3 in combination with cisplatin 75 mg/m<sup>2</sup> intravenously on day 1 (EP) or carboplatin AUC=5 every 3 weeks (EC). The selection of the regimen depends on the decision of the investigators. In cases of intolerance to chemotherapeutic agents, dose modifications are allowed twice according to the prescribing information for cisplatin/carboplatin and etoposide.

Thoracic radiation will be initiated no later than two cycles after chemotherapy[27]. It is planned to target the primary tumor and involved mediastinal lymph node regions. For simulation, 4D-CT simulation positioning and enhanced CT positioning image scanning should be performed as much as possible. The scanning slice thickness was 0.3 cm. A total of 45 Gy in 15 fractions over 3 weeks will be delivered. PCI is routinely scheduled for patients without progression after chemoradiotherapy. 25Gy in 10 fractions over 2 weeks to the brain will be prescribed. Image guided-intensity modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) techniques are needed. Treatment plans should meet organ dose constraints, as listed in Table 2. Patients without disease progression will receive an intravenous infusion of 300 mg serplulimab every 3 weeks. Treatment with serplulimab should be continued until disease progression, intolerable toxicity, withdrawal of consent, or a maximum of 1 year.

**Assessment**

Treatment response will be assessed every 4 cycles during serplulimab treatment with chest CT and brain magnetic resonance imaging (MRI) and ultrasonic examination when necessary. Contrast-enhanced CT of the neck, thorax and abdomen is preferred. Brain CT or PET is allowed if MRI is contraindicated. Each CT and MRI scan needs to be reviewed by radiologists and radiation oncologists. Subsequent assessments and follow-up will be performed every 6 weeks during the first 48 weeks of treatment and every 9 weeks after 48 weeks.

Patients will be interviewed face to face during their routine hospital visits and by telephone 1-2 weeks after delivery. Adverse events will be evaluated at each visit. Grades of side effects using CTCAE 5.0 and their relationship with immunotherapy will be assessed by the research team members. Grade 2 pneumonia and grade 3 to 4 adverse effects will be managed by drug interruption and symptomatic treatment. Of note, dose reduction of serplulimab is not permitted.

**Statistical considerations and analysis**

The primary purpose of the phase II study was to evaluate the improvement in PFS for LS-SCLC patients. The study adopted the design of a superior test, and the

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

sample size was calculated using historical data as a reference. The median PFS of LS-SCLC patients treated with standard CRT and PCI is approximately 15 months. The assumption of 80% power, a significance level of 10%, a hazard ratio of 0.65, an accrual period of 12 months, and a minimum follow-up of 27 months resulted in a sample size of 50 individuals. Considering a maximum drop-out rate of 10%, a total of 55 patients will be recruited in ASTRUM-LC01. The sample size calculation was performed using the Power Analysis and Sample Size (PASS) software, version 15.

All collected data will enter the computer. Measurement data will be described as the median, mean value and standard deviation. Enumeration data will be described as the number of cases and percentage. Kaplan–Meier survival analysis and Cox regression will be applied for survival analysis. The log-rank method will be used for comparison between subgroups. A value of 0.05 was set as the statistically significant standard in this trial.

### Monitoring

The study group will review data about treatment efficacy and safety. Trial monitoring is planned every half-a-year, and the monitoring committee will modify the protocol if necessary. Trial progress will be monitored by the study group, same as safety and protocol compliance.

### Patient and Public Involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research

### Discussion

Small cell lung cancer is a highly aggressive cancer with poor prognosis. Therefore, there is a great need to improve treatment efficacy, especially in the era of precision radiation and immunotherapy. Based on current evidence, immunotherapy has shown high efficacy as consolidation therapy in locally advanced NSCLC. The landscape of ES-SCLC treatment has also been significantly impacted by the increasing evidences of combining immunotherapy and chemotherapy in first line. Whether consolidation

immunotherapy would bring added benefits to traditional concurrent chemoradiotherapy in LS-SCLC has attracted much attention worldwide. This clinical trial was therefore designed to answer this question.

Serplulimab, a novel humanized monoclonal anti-PD-1 antibody, has emerged as a promising agent in this context. The ASTRUM-005 study demonstrated that serplulimab was the first PD-1 antibody to show positive results in the first-line treatment of ES-SCLC with advanced survival data, marking a milestone in the immunotherapy exploration process and the history of SCLC treatment[7]. Meanwhile,  $\geq$ grade 3 adverse effect of serplulimab was similar to other drugs. Hence, we expect improved survival with acceptable toxicity in this trial, with great confidence.

The optimal duration of consolidation remains controversial. At the initiation of this trial in 2022, the only trial with results published, STIMULI trial, adopted a similar design as the classic PACIFIC trial[8]. Its failure was considered to be mainly due to treatment toxicity. The GEMSTONE-301 study and the recently published ADRIATIC study have opted for a longer duration of 2 years, and both significantly prolonged survival versus placebo[9,28]. But the 2-year consolidation therapy in GEMSTONE-301 trial did not demonstrate survival benefits beyond the PACIFIC pattern. Taking both the potential benefits of extended therapy and the costs into consideration, our study set the duration of serplulimab consolidation therapy to 1 year. But whether extended exposure to immunotherapy consolidation could potentially enhance its therapeutic effects will need further investigation.

Different from conventional or hyperfractionated RT in ADRIATIC trial, hypofractionated thoracic radiation was scheduled during CRT in our study. This cost-effective regimen is permitted and recommended by NCCN guideline. Synergistic effect of RT and immunotherapy might be dose-dependent as mentioned before. Further research is necessary to define the precise parameters for combining RT with immunotherapy to achieve the best clinical outcomes.

There are some limitations of this trial. The single-arm design with small sample size may limit the generalizability of the findings. Also, since only Chinese patients

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

will be enrolled, the applicability of the results to other regions with different healthcare systems and patient populations.

In summary, this trial design comprehensively optimized treatment paradigm with the expectation of further improving the prognosis of LS-SCLC patients.

### **Ethics and dissemination**

This study received ethical approval from the Independent Ethics Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (22/236-3438). This protocol has been accepted for poster presentation at the European Lung Cancer Congress (ELCC) 2024. Investigators will obtain written consent from patients willing to participate in the trial.

### **List of abbreviation**

CI: confidence interval

CR: complete response

EC: etoposide and carboplatin

ECOG PS: Eastern Cooperative Oncology Group performance status

EP: etoposide and cisplatin

ES-SCLC: extensive-stage small cell lung cancer

HR: hazard ratio

IMRT: image guided-intensity modulated radiation therapy

LS-SCLC: limited-stage small cell lung cancer

MRI: magnetic resonance imaging

ORR: objective response rate

OS: overall survival

PCI: prophylactic cranial irradiation

PFS: Progression-free survival

PR: partial response

SCLC: Small cell lung cancer

TTF: time to treatment failure  
VALSG: Veterans Administration Lung Study Group  
VMAT: volumetric modulated arc therapy

Authors’ Contributions

The study was designed by YW, LD, JC and NB. YW and JC developed the statistical analysis plan. YW and LD were major contributors in writing the manuscript. LD, JW, TZ, JC and XZ perform the research and monitor progress. JC, XZ and NB modified the manuscript. All authors read and approved the final manuscript. NB acted as guarantor.

Competing interests

The authors declare that they have no competing interests.

Funding statement

This study was supported by the Beijing Municipal Science & Technology Commission (No. Z221100007422011).

Acknowledgments

Serplulimab in this trial will be provided by Shanghai Henlius Biotech, Inc., for free. This had no influence on the trial design, statistical analysis, or publication.

Reference

1. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primer. 2021 Jan 14;7(1):3.
2. Bogart JA, Waqar SN, Mix MD. Radiation and Systemic Therapy for Limited-Stage Small-Cell Lung Cancer. J Clin Oncol. 2022 Feb 20;40(6):661–70.
3. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol Off J Am Soc Clin Oncol. 2021 Feb 20;39(6):619–30.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).



4. Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. *The Lancet*. 2019 Nov;394(10212):1929–39.
5. Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2022 Jun;23(6):739–47.
6. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. *J Clin Oncol*. 2020 Jul 20;38(21):2369–79.
7. Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer: The ASTRUM-005 Randomized Clinical Trial. *JAMA*. 2022 Sep 27;328(12):1223–32.
8. Peters S, Pujol JL, Dafni U, Dómine M, Popat S, Reck M, et al. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. *Ann Oncol Off J Eur Soc Med Oncol*. 2022 Jan;33(1):67–79.
9. Senan S, Okamoto I, Lee G won, Chen Y, Niho S, Mak G, et al. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. *Clin Lung Cancer*. 2020 Mar;21(2):e84–8.
10. Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y, et al. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2024 Oct 10;391(14):1313–27.
11. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. *N Engl J Med*. 1999 Jan 28;340(4):265–71.
12. Farrell MJ, Yahya JB, Degnin C, Chen Y, Holland JM, Henderson MA, et al. Radiation Dose and Fractionation for Limited-stage Small-cell Lung Cancer: Survey of US Radiation Oncologists on Practice Patterns. *Clin Lung Cancer*. 2019 Jan;20(1):13–9.

13. Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Oncol*. 2017 Aug;18(8):1116–25.

14. Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE, et al. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. *J Clin Oncol*. 2023 Jan 9;JCO.22.01359.

15. Socha J, Guzowska A, Tyc-Szczepaniak D, Szczęśna A, Kępka L. Hypofractionated conformal radiotherapy in combination with chemotherapy in limited disease small cell lung cancer patients. *Pneumonol Alergol Pol*. 2014;82(2):105–15.

16. Gronberg BH, Halvorsen TO, Flotten O, Brustugun OT, Brunsvig PF, Aasebo U, et al. Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. *Acta Oncol*. 2016 May;55(5):591–7.

17. Xia B, Hong LZ, Cai XW, Zhu ZF, Liu Q, Zhao KL, et al. Phase 2 study of accelerated hypofractionated thoracic radiation therapy and concurrent chemotherapy in patients with limited-stage small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2015 Mar 1;91(3):517–23.

18. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, et al. Locoregional failures following thoracic irradiation in patients with limited-stage small cell lung carcinoma. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 2012 Feb;102(2):263–7.

19. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. *J Exp Med*. 2006 May 15;203(5):1259–71.

20. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. *Blood*. 2009 Jul 16;114(3):589–95.

21. Stry V, Wolf B, Unterleuthner D, List J, Talic M, Laengle J, et al. Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer. *J Immunother Cancer*. 2020 Aug;8(2):e000667.

22. Wang Y, Liu ZG, Yuan H, Deng W, Li J, Huang Y, et al. The Reciprocity between Radiotherapy and Cancer Immunotherapy. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2019 Mar 15;25(6):1709–17.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

23. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. *Nat Commun*. 2017 Jun 9;8:15618.
24. Weichselbaum RR, Liang H, Deng L, Fu YX. Radiotherapy and immunotherapy: a beneficial liaison? *Nat Rev Clin Oncol*. 2017 Jun;14(6):365–79.
25. Haikerwal SJ, Hagekyriakou J, MacManus M, Martin OA, Haynes NM. Building immunity to cancer with radiation therapy. *Cancer Lett*. 2015 Nov 28;368(2):198–208.
26. Formenti SC, Demaria S. Systemic effects of local radiotherapy. *Lancet Oncol*. 2009 Jul;10(7):718–26.
27. Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, et al. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. *Ann Oncol Off J Eur Soc Med Oncol*. 2013 Aug;24(8):2088–92.
28. Zhou Q, Chen M, Jiang O, Pan Y, Hu D, Lin Q, et al. Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol*. 2022 Feb;23(2):209–19.

## Figure Legends & Tables

**Figure 1** Flowchart of the ASTRUM-LC01 study. SCLC: Small cell lung cancer; ECOG PS: Eastern Cooperative Oncology Group performance status; PCI: Prophylactic cranial irradiation; PFS: Progression-free survival; OS: Overall survival; ORR: Objective response rate; DCR: TTF: Time to treatment failure.

**Table 1** Inclusion criteria and exclusion criteria.

Inclusion criteria	Exclusion criteria
--------------------	--------------------

Aged 18-75 years.	Histologically or cytologically confirmed mixed SCLC.
Histologically or cytologically confirmed SCLC.	Suitable for surgery.
Limited stage SCLC.	Patients with other active malignancies within 5 years or at the same time. Localized tumors that have been cured such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder carcinoma, prostate carcinoma in situ, cervical carcinoma in situ, and breast cancer in situ are acceptable.
Score of Eastern Cooperative Oncology Group performance status (ECOG PS) being 0 or 1.	Patients with pleural, pericardial effusions, or ascites requiring clinical intervention.
Without previous anti-tumor treatment history	Uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN).
Without serious abnormalities in hematopoietic function or cardiac, hepatic, or renal function, or immunodeficiency.	Patients with peripheral neuropathy ≥ grade 2 by CTCAE.
Expected survival of at least 3 months	Patients with human immunodeficiency virus (HIV), Hepatitis B or C infection.
Voluntarily participate in this clinical study and signed the informed consent form.	Patients with active pulmonary tuberculosis, previous and current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, and severe impaired pulmonary function as judged by the investigator.


	Subjects with known active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to be enrolled.
--	---

**Table 2 Organ at risk dose constrains.**

Organ at risk		
Lung	V20 < 25%	mean lung dose $\leq$ 15 Gy
Spinal cord PRV*	Dmax < 42Gy	
Esophagus	Dmax < 50 Gy	mean dose < 34 Gy
Heart	V30 < 50%	
Hippocampus	Dmax < 9 Gy	
Hippocampus PRV**	Dmax < 12 Gy	

\*5 mm expansion outside the spinal cord to form planning organ-at-risk volume (PRV)

\*\* 2 mm expansion outside hippocampus to form PRV



Flowchart of the ASTRUM-LC01 study.  
254x142mm (400 x 400 DPI)